ADC Therapeutics S.A.(ADCT)

$1.03—

Chart

ADC Therapeutics S.A.(ADCT)

NYSE

$1.03—

Chart Studio

ADCT(ADCT)

ADCT

Overview Fair Value Stream Notebook Intel Chart History Fundamentals TTM Earnings Analysts News Financials Segments Insiders Institl.DCF Peers

Q4 2026 EPS Estimate

$-0.21

Nov 10, 2026 · Reports before open

Revenue Estimate

$19M

FY2029E EPS$0.33

FY2030E EPS$0.55

Analyst Sentiment

Wall St. Consensus

Hold

11 analysts·Moderate coverage

Score

5 Buy (45%)5 Hold (45%)1 Sell (10%)

Rating Breakdown

Strong Buy

00%

Buy

545%

Hold

545%

Sell

19%

Strong Sell

00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Bear

$2.00

+94.2%

Consensus

$3.50

+239.8%

Bull

$5.00

+385.4%

12-Month Target Range11 analysts

$2.00$3.50$5.00

Current $1.03Consensus

Current Price

$1.03

Upside to Consensus

$2.47

Price targets are 12-month analyst forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

Forward Growth Estimates (YoY)

FY2027

Rev+43.22%

EPS—

FY2028

Rev+78.83%

EPS—

FY2029

Rev+47.80%

EPS—

Raw consensus estimates (low / average / high) from covering analysts.

Annual

Metric	FY2026E	FY2027E	FY2028E	FY2029E	FY2030E
Revenue Avg	$80M	$115M	$205M	$304M	$339M
Low	$66M	$86M	$138M	$249M	$278M
High	$98M	$134M	$302M	$372M	$416M
EBITDA Avg	$-72M	$-104M	$-185M	$-274M	$-306M
Low	$-89M	$-121M	$-273M	$-336M	$-375M
High	$-59M	$-77M	$-125M	$-225M	$-251M
EBIT Avg	$-73M	$-104M	$-186M	$-275M	$-307M
Low	$-89M	$-121M	$-273M	$-337M	$-376M
High	$-59M	$-77M	$-125M	$-225M	$-252M
Net Income Avg	$-109M	$-87M	$-8M	$42M	$69M
Low	$-111M	$-109M	$-199M	$32M	$53M
High	$-106M	$-64M	$162M	$55M	$90M
EPS Avg	$-0.86	$-0.66	$-0.27	$0.33	$0.55
Low	$-0.88	$-0.86	$-1.57	$0.26	$0.42
High	$-0.84	$-0.51	$1.27	$0.43	$0.71
Analysts (Rev / EPS)	3 / 3	4 / 3	4 / 4	2 / 1	2 / 1

Quarterly

Metric	Q3 2026	Q4 2026	Q1 2027	Q2 2027	Q3 2027	Q4 2027
Revenue Avg	$19M	$22M	$21M	$21M	$31M	$45M
Low	$17M	$19M	$19M	$19M	$28M	$41M
High	$22M	$29M	$24M	$24M	$35M	$51M
EBITDA Avg	$-17M	$-20M	$-19M	$-19M	$-28M	$-41M
Low	$-19M	$-26M	$-21M	$-21M	$-32M	$-46M
High	$-16M	$-17M	$-17M	$-17M	$-26M	$-37M
EBIT Avg	$-17M	$-20M	$-19M	$-19M	$-28M	$-41M
Low	$-20M	$-26M	$-21M	$-21M	$-32M	$-46M
High	$-16M	$-17M	$-17M	$-17M	$-26M	$-37M
Net Income Avg	$-33M	$-32M	$-28M	$-29M	$-23M	$-14M
Low	$-39M	$-36M	$-33M	$-35M	$-27M	$-16M
High	$-30M	$-27M	$-25M	$-26M	$-21M	$-12M
EPS Avg	$-0.22	$-0.20	$-0.18	$-0.19	$-0.15	$-0.09
Low	$-0.25	$-0.23	$-0.21	$-0.22	$-0.18	$-0.11
High	$-0.19	$-0.17	$-0.16	$-0.17	$-0.13	$-0.08
Analysts (Rev / EPS)	3 / 3	5 / 5	4 / 3	4 / 3	4 / 3	4 / 3

Earnings Surprises

Recent Analyst Actions

Jun 4, 2026Stephens

ADC Therapeutics price target lowered to $5 from $8 at Stephens

Target:$5.00

+243.6%from $1.46

Jun 4, 2026RBC Capital

ADC Therapeutics downgraded to Sector Perform from Outperform at RBC Capital

Target:$2.00

-35.1%from $3.08

Dec 3, 2025RBC Capital

RBC Capital on ADC Therapeutics (ADCT): 'We think the downside is unwarranted and would be buyers on weakness'

Target:$5.00

+26.4%from $3.96

Nov 12, 2025Guggenheim

Guggenheim Reiterates Buy Rating on ADC Therapeutics (ADCT)

Target:$10.00

+151.9%from $3.97

May 7, 2024H.C. Wainwright

ADC Therapeutics (ADCT) PT Lowered to $8 at H.C. Wainwright

Target:$8.00

+79.8%from $4.45

Mar 13, 2024Jefferies

ADC Therapeutics (ADCT) PT Lowered to $13 at Jefferies

Target:$13.00

+233.3%from $3.90

Nov 14, 2022Morgan Stanley

Morgan Stanley Maintains Equal-Weight on ADC Therapeutics, Lowers Price Target to $7

Target:$7.00

+70.7%from $4.10

Sep 9, 2022Morgan Stanley

ADC Therapeutics downgraded to Equal Weight from Overweight at Morgan Stanley

Target:$11.00

+68.7%from $6.52

Aug 22, 2022H.C. Wainwright

HC Wainwright & Co. Maintains Buy on ADC Therapeutics, Lowers Price Target to $20

Target:$20.00

+137.5%from $8.42

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance